Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands	Jun. 30, 2025	Dec. 31, 2024	May 12, 2023	Aug. 26, 2021
Liabilities:
Common stock warrant liabilities	$ 4,358	$ 19,254
Private Placement Warrants
Liabilities:
Common stock warrant liabilities	100	400		$ 600
Recurring
Assets:
Common Stock Purchase Agreement derivative asset	672	672
Total financial assets	32,813	32,716
Liabilities:
Contingent Earnout Liability	26,700	70,961
Total financial liabilities	34,372	92,815
Recurring \| Private Placement Warrants
Liabilities:
Common stock warrant liabilities	136	385
Recurring \| October 2024 Registered Direct Offering Warrants
Liabilities:
Common stock warrant liabilities	2,811	12,437
Recurring \| November 2024 Registered Direct Offering Warrants
Liabilities:
Common stock warrant liabilities	1,411	6,432
Recurring \| Contingent derivative liability
Liabilities:
Derivative liability	3,161	2,415	$ 2,400
Recurring \| Option Agreement liability
Liabilities:
Derivative liability	27	64	$ 55
Recurring \| JDRF Agreement derivative liability
Liabilities:
Derivative liability	126	121
Recurring \| Level 1
Assets:
Common Stock Purchase Agreement derivative asset	0	0
Total financial assets	32,141	32,044
Liabilities:
Contingent Earnout Liability	0	0
Total financial liabilities	0	0
Recurring \| Level 1 \| Private Placement Warrants
Liabilities:
Common stock warrant liabilities	0	0
Recurring \| Level 1 \| October 2024 Registered Direct Offering Warrants
Liabilities:
Common stock warrant liabilities	0	0
Recurring \| Level 1 \| November 2024 Registered Direct Offering Warrants
Liabilities:
Common stock warrant liabilities	0	0
Recurring \| Level 1 \| Contingent derivative liability
Liabilities:
Derivative liability	0	0
Recurring \| Level 1 \| Option Agreement liability
Liabilities:
Derivative liability	0	0
Recurring \| Level 1 \| JDRF Agreement derivative liability
Liabilities:
Derivative liability	0	0
Recurring \| Level 2
Assets:
Common Stock Purchase Agreement derivative asset	672	672
Total financial assets	672	672
Liabilities:
Contingent Earnout Liability	0	0
Total financial liabilities	0	0
Recurring \| Level 2 \| Private Placement Warrants
Liabilities:
Common stock warrant liabilities	0	0
Recurring \| Level 2 \| October 2024 Registered Direct Offering Warrants
Liabilities:
Common stock warrant liabilities	0	0
Recurring \| Level 2 \| November 2024 Registered Direct Offering Warrants
Liabilities:
Common stock warrant liabilities	0	0
Recurring \| Level 2 \| Contingent derivative liability
Liabilities:
Derivative liability	0	0
Recurring \| Level 2 \| Option Agreement liability
Liabilities:
Derivative liability	0	0
Recurring \| Level 2 \| JDRF Agreement derivative liability
Liabilities:
Derivative liability	0	0
Recurring \| Level 3
Assets:
Common Stock Purchase Agreement derivative asset	0	0
Total financial assets	0	0
Liabilities:
Contingent Earnout Liability	26,700	70,961
Total financial liabilities	34,372	92,815
Recurring \| Level 3 \| Private Placement Warrants
Liabilities:
Common stock warrant liabilities	136	385
Recurring \| Level 3 \| October 2024 Registered Direct Offering Warrants
Liabilities:
Common stock warrant liabilities	2,811	12,437
Recurring \| Level 3 \| November 2024 Registered Direct Offering Warrants
Liabilities:
Common stock warrant liabilities	1,411	6,432
Recurring \| Level 3 \| Contingent derivative liability
Liabilities:
Derivative liability	3,161	2,415
Recurring \| Level 3 \| Option Agreement liability
Liabilities:
Derivative liability	27	64
Recurring \| Level 3 \| JDRF Agreement derivative liability
Liabilities:
Derivative liability	126	121
Recurring \| Cash equivalents (money market funds)
Assets:
Cash equivalents (money market funds)	32,141	32,044
Recurring \| Cash equivalents (money market funds) \| Level 1
Assets:
Cash equivalents (money market funds)	32,141	32,044
Recurring \| Cash equivalents (money market funds) \| Level 2
Assets:
Cash equivalents (money market funds)	0	0
Recurring \| Cash equivalents (money market funds) \| Level 3
Assets:
Cash equivalents (money market funds)	$ 0	$ 0

Humacyte, Inc. 10-Q